Thermo Fisher Scientific Announces R&D Partnership with AstraZeneca BioVentureHub
The PPD™ clinical research business of Thermo Fisher Scientific, the world leader in serving science, today announced a new research and development (R&D) partnership with the AstraZeneca BioVentureHub in Gothenburg, Sweden.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251001395504/en/
Thermo Fisher Bioanalytical lab
The partnership aims to leverage the combined expertise of Thermo Fisher and AstraZeneca to drive innovation and strengthen the life science ecosystem. A dedicated team from Thermo Fisher will co-locate with AstraZeneca scientists to work on collaborative R&D projects with a focus initially on chromatography, molecular genomics and proteomics.
"This is a unique opportunity to co-locate with AstraZeneca scientists, driving collaborative innovation, strengthening the science ecosystem and driving value generation for all collaborators, giving easy access to cutting edge technologies for emerging life sciences and biotech companies as well as academic groups,” said Leon Wyszkowski, president, analytical services, clinical research, Thermo Fisher Scientific. “This partnership will enable advancements in areas such as drug and analytical development, further bringing to life Thermo Fisher's mission to enable our customers to make the world healthier, cleaner and safer."
“When two global life science leaders join forces in an open innovation environment, truly exceptional conditions for breakthrough discovery and progress are created. Welcoming Thermo Fisher Scientific into BioVentureHub at AstraZeneca’s strategic R&D campus in Gothenburg - adjacent to GoCo Health Innovation City - marks a significant step and unlocks dynamic opportunities for open scientific co-creation between AstraZeneca and Thermo Fisher Scientific. We are pleased to welcome the Thermo Fisher team and look forward to a highly productive partnership,"Magnus Björsne, CEO, AstraZeneca BioVentureHub said.
The AstraZeneca BioVentureHub is part of a growing innovation ecosystem in Gothenburg that includes the GoCo Health Innovation City, future home of Thermo Fisher's bioanalytical laboratory that is under construction and expected to begin operations in March 2026. This state-of-the-art facility will serve pharmaceutical and biotech customers in Europe and across the globe, providing leading-edge bioanalytical laboratory capabilities to support all phases of pharmaceutical development to help customers deliver life-changing medicines to patients worldwide.
In addition to the new lab coming online in Sweden, the business operates a global network of GMP (good manufacturing practices), central, bioanalytical and vaccine science laboratories with operations based in Middleton, Wisconsin; Highland Heights, Kentucky; Richmond, Virginia; Athlone, Ireland; Brussels, Belgium; Singapore; and Suzhou, China.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivalled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
For more information, please visit www.thermofisher.com.
About AstraZeneca BioVentureHub
AstraZeneca BioVentureHub is a unique open innovation platform, offering an inside track to AstraZeneca's scientific expertise, world-class infrastructure, and facilities. Integrated at the heart of AstraZeneca's strategic R&D site in Gothenburg, the BioVentureHub enables emerging life science companies and academia to work and grow within our focus areas: Pharma, DeepTech, Digital & SustainTech.
We promote innovation by connecting, catalyzing, and nurturing the right parties to form valuable collaborations that drive growth for all involved. Our unique dare-to-share culture, trust, and scientific curiosity, together with non-competitive synergies, are at the core of being part of the BioVentureHub. All BioVentureHub companies operate independently, and AstraZeneca holds no ownership or innovation rights. The BioVentureHub is a fusion of minds and resources leading to groundbreaking innovations and industry leadership. We believe in Growing Innovation Together. For more information, please visit www.azbioventurehub.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20251001395504/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
QNB Group Receives Saudi Central Bank “SAMA” License Approval for a New Digital Bank “ezbank”1.10.2025 18:20:00 CEST | Press release
In co-operation with Ajlan & Bros. Holding Introducing a new model of customer-centric banking built around innovation, efficiency, and accessibility. Providing innovative solutions for the youth and entrepreneurs. QNB Group, the largest financial institution in the Middle East and Africa, announced the license approval has been received for a digital-first banking entity, ezbank, from the Saudi Central Bank ”SAMA”, in cooperation with Ajlan & Bros. Holding, with a capital of SAR 2.5 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251001012393/en/ QNB Group Corporate Headquarters (Photo: AETOSWire) This milestone, in cooperation with Ajlan & Bros. Holding, reflects a commitment to supporting QNB Group’s vision for financial inclusion and digital transformation, as well as the broader economic development strategy. With ezbank, the goal is to introduce a new model of customer-centric banking built around innovation, e
CompareForexBrokers: Seven Major Forex Pairs Slip to 66.3% of Global Turnover1.10.2025 17:02:00 CEST | Press release
2025 BIS Triennial Survey data shows major pair concentration down 18.7% from 2022 CompareForexBrokers has analysed the latest Triennial Survey from the Bank for International Settlements, published 30 September 2025, and found the seven major currency pairs are losing dominance in global foreign exchange markets. While 85% of forex transactions consisted of the seven majors in 2022, their share has since dropped to 66.3% in 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251001844788/en/ Daily Turnover On Forex Markets Despite the 18.7% drop in major pairs, overall activity has increased considerably, with daily turnover rising 28% to 9.6 trillion USD. On an annual basis, that equates to 3.5 quadrillion USD, up from 2.73 quadrillion in 2022. More data can be found on the forex statistics page. “Our biggest take away from yesterday’s BIS data release is foreign exchange remains the largest financial market, but the comp
Pure Lithium Partners with Voltaiq to Accelerate Commercialization1.10.2025 15:15:00 CEST | Press release
Voltaiq’s battery quality analytics platform to power the commercialization of Pure Lithium’s lithium metal battery technology Pure Lithium, a disruptive vertically integrated lithium metal battery technology company, has selected Voltaiq’s Enterprise Battery Intelligence platform to provide battery analytics and quality control that are essential to Pure Lithium’s drive to commercialize its next generation lithium metal battery, the two companies announced today. The partnership with Voltaiq, the industry leader in battery quality analytics software, comes at a crucial time for Pure Lithium as it relocates to Chicago, builds out its first pilot line, and begins shipping sample cells to customers. Pure Lithium previously relied on its own internal analytics system. As the company shifts focus from R&D to commercialization, the team turned to Voltaiq to provide a platform that can scale with the business – including advanced analytics – as well as a partner with deep battery and softwar
Blue Matter Hires New Partner, Eva Kersey, Further Strengthening Capabilities in Europe1.10.2025 15:05:00 CEST | Press release
Blue Matter is pleased to announce that Eva Kersey has joined the firm as a Partner based in London. Eva officially joined the Blue Matter team on September 16, bringing a broad base of strategic consulting experience across pharmaceutical, biotech, and medical technology clients. Eva has been serving life science clients since 2007. She began her consulting career at PHP (now a part of Accenture). Since then, she has served in leadership and Partner-level positions at IMS Consulting, IQVIA, and ClearView Healthcare Partners. Over the years, her consulting experience has spanned the full value chain, focusing on cross-functional strategy development. She brings a particular specialization in therapy and franchise strategy, portfolio optimization, and pricing, access and evidence strategy. She also brings significant expertise in all aspects of commercial strategy development for clinical-stage, pre-launch assets. “I’m extremely excited to join the Blue Matter team,” Eva said. “The firm
NIQ’s State of Beauty 2025: Beauty Breaks Boundaries with 10% Growth, Digital Surge & Wellness Shift1.10.2025 15:00:00 CEST | Press release
Beauty sales have grown by 10% in the past 12 months, outpacing previous performanceOnline beauty sales are growing 9x faster than in-store, with North America (+21%), Asia Pacific (+20%), and Europe (+10%) all seeing double-digit online growth.“Tweakments,” are reshaping traditional skincare routines - Thirty-five percent of US respondents say they will change their skincare routine after getting a procedure.Wellness and ritual now expand the beauty opportunity by 64%, as consumers embrace self-care routines that go beyond appearance. NielsenIQ (NYSE: NIQ) today released its State of Beauty 2025 report, revealing a beauty industry that’s not only thriving — it’s transforming. With global beauty sales up 10% year-over-year, the sector is expanding its definition, embracing digital-first strategies, and wellness rituals that are reshaping consumer behavior. Global Growth: Asia Pacific Leads, Consumers Spend More, Shop More Often Beauty’s resilience is undeniable. Despite economic pressu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom